argenx announces full exercise of underwritersa?? option to purchase additional ADSs

Regulated information a?? Inside information
May 29, 2020Breda, the Netherlands / Ghent, Belgium a?? argenx (EuronextA & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)) have exercised their option to purchase 548,777 additional ADSs in full on the same terms and conditions as the global offering. This option exercise brings the anticipated total gross proceeds from the global offering to approximately $862.5 million (approximately a?¬784.7 million) from the sale of an aggregate of 4,207,292 ordinary shares (including ordinary shares represented by ADSs).J.P. Morgan, Cowen and BofA Securities acted as joint bookrunning managers for the offering. Stifel, JMP Securities, Wedbush PacGrow, Nomura and Kempen & Co acted as co-managers for the offering.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2020    »